logo-loader

Silence Therapeutics morphing into commercial drug company

Published: 15:14 01 May 2014 BST

Ali Mortazavi, chief executive of Silence Therapeutics (LON:SLN) tells Proactive Investors that it is transforming into a product company as it tailors its development technologies into commercial drugs.

Oriole Resources outlines 2023 achievements and future exploration plans

Oriole Resources PLC (AIM:ORR) CEO Tim Livesey and chief financial officer Bob Smeeton join Proactive's Stephen Gunnion with details of the company's 2023 financial and operational performance. Livesey highlighted successful exploration programs in Cameroon, at the Bibemi and Mbe projects,...

37 minutes ago